Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries-Reference-Cited by-同舟云学术

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

Published:2018-07-20 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Kamusheva Maria,Manova Manoela,Savova Alexandra T.,Petrova Guenka I.,Mitov Konstantin,Harsányi András,Kaló Zoltán,Márky Kristóf,Kawalec Pawel,Angelovska Bistra,Lakić Dragana,Tesar Tomas,Draganic Pero,Geitona Mary,Hatzikou Magdalini,Paveliu Marian S.,Männik Agnes

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference38 articles.

1. Integrating common and rare genetic variation in diverse human populations;Altshuler;Nature,2010

2. High-content drug screening for rare diseases;Bellomo;J. Inheri. Metab. Dis.,2017

3. Gene therapy: the view from NCATS;Brooks;Hum. Gene Ther.,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries;Frontiers in Pharmacology;2024-03-08

2. Making orphan drugs and services available and accessible for people who live with rare diseases: what has been done? a systematic scoping review;Expert Opinion on Orphan Drugs;2022-12-02

3. Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study;Frontiers in Pharmacology;2022-09-30

4. Analysis of Publication Activity and Patent Activity in Biotechnology from 2001 to 2020.;Science Management: Theory and Practice;2022-03-28

5. Rare disease patients’ needs: an up-to-date analysis and future directions;Pharmacia;2021-10-06